Via The Lancet Respiratory Medicine, an alarming report: Pulmonary fibrosis secondary to COVID-19: a call to arms? Excerpt:
Other strains of the coronavirus family, namely severe acute respiratory syndrome coronavirus (SARS-CoV; known as SARS) and Middle East respiratory syndrome coronavirus (MERS-CoV; known as MERS), are genetically similar to SARS-CoV-2 and cause pulmonary syndromes similar to COVID-19. At the end of the SARS epidemic in June, 2003, 8422 individuals were affected and 916 died; whereas MERS, which was first identified in April, 2012, has infected 2519 individuals worldwide to date, including 866 deaths.
The predominant CT abnormalities in patients with SARS included rapidly progressive ground glass opacities sometimes with consolidation. Reticular changes were evident approximately 2 weeks after symptom onset and persisted in half of patients beyond 4 weeks. However, a 15-year follow-up study of 71 patients with SARS showed that interstitial abnormalities and functional decline recovered over the first 2 years following infection and then remained stable.
At 15 years, 4·6% (SD 6·4%) of the lungs showed interstitial abnormality in patients who had been infected with SARS. In patients with MERS, typical CT abnormalities included bilateral ground glass opacities, predominantly in the basal and peripheral lung zones. Follow-up outcomes are less well described in patients with MERS. In a study of 36 patients who had recovered from MERS, chest x-rays taken a median of 43 (range 32–320) days after hospital discharge showed abnormalities described as lung fibrosis in about a third of the patients. Longer-term follow-up of patients who recovered from MERS has not been reported.
Pulmonary fibrosis can develop either following chronic inflammation or as a primary, genetically influenced, and age-related fibroproliferative process, as in idiopathic pulmonary fibrosis (IPF). Pulmonary fibrosis is a recognised sequel of ARDS. However, most follow-up studies—which have included both physiological measures and chest CT—have shown that persistent radiographic abnormalities after ARDS are of little clinical relevance and have become less common in the era of protective lung ventilation.
Available data indicate that about 40% of patients with COVID-19 develop ARDS, and 20% of ARDS cases are severe. Of note, the average age of patients hospitalised with severe COVID-19 appears to be older than that seen with MERS or SARS, which is perhaps a consequence of wider community spread. In inflammatory lung disorders, such as those associated with autoimmune disease, advancing age is a risk factor for the development of pulmonary fibrosis. Given these observations, the burden of pulmonary fibrosis after COVID-19 recovery could be substantial.
Progressive, fibrotic irreversible interstitial lung disease, which is characterised by declining lung function, increasing extent of fibrosis on CT, worsening symptoms and quality of life, and early mortality,10 arises, with varying degrees of frequency, in the context of a number of conditions including IPF, hypersensitivity pneumonitis, autoimmune disease, and drug-induced interstitial lung disease.
Although the virus is eradicated in patients who have recovered from COVID-19, the removal of the cause of lung damage does not, in itself, preclude the development of progressive, fibrotic irreversible interstitial lung disease. Furthermore, even a relatively small degree of residual but non-progressive fibrosis could result in considerable morbidity and mortality in an older population of patients who had COVID-19, many of whom will have pre-existing pulmonary conditions.
At present, the long-term pulmonary consequences of COVID-19 remains speculative and should not be assumed without appropriate prospective study. Nonetheless, given the huge numbers of individuals affected by COVID-19, even rare complications will have major health effects at the population level. It is important that plans are made now to rapidly identify whether the development of pulmonary fibrosis occurs in the survivor population. By doing this, we can hope to deliver appropriate clinical care and urgently design interventional trials to prevent a second wave of late mortality associated with this devastating pandemic.
